Contraline

• ·Contraline’s last known valuation is $60.0M (Feb 2025).
• ·It has raised $41.7M across 3 recorded rounds; the latest was Later Stage VC ($55.8M) in May 2026.
• ·Notable investors include Alumni Ventures, Kima Ventures, Gaingels, Metaplanet Holdings, GV — 52 tracked in total.
• ·3 investment vehicles were formed to buy Contraline shares in the last 12 months, reporting $2.3M sold to 106 investors, per SEC Form D filings.
• ·Contraline has filed 1 Form D with the SEC, most recently Apr 2022 ($7.2M sold to 22 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 3 investment vehicles were formed to buy Contraline shares, reporting $2.3M sold to 106 investors across 3 sponsors. Most recent filing Jun 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of a male contraceptive product intended to provide non-surgical and reversible birth control procedures. The company's technology implants a non-hormonal, non-surgical, and reversible polymer hydrogel into the vas deferens for contraception and acts as a semi-permeable membrane, blocking sperm while allowing fluids through, enabling users to get a cost-effective approach to contraception easily.

Industry

Drug Discovery

Sector

Healthcare

HQ

Charlottesville, VA, United States

Founded

2015

Employees

23

Website

contraline.com/

Ownership

Privately Held (backing)